FWD1802
Phase 2Small molecule
FWD1802 is one of 52 small molecule programs targeting Phase IB. It is currently in Phase 2.
2
Indications
3
Total Trials
3
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
46 competitors in Advanced
#DrugCompanyPhaseTrials
1Remodulin
United TherapeuticsPhase 3
Tecentriq
RochePhase 2
Qinlock
DDeciphera Pharmaceuticals, LLC
Phase 3
Lenvima
EisaiPhase 2
Fludara
SanofiPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Cabometyx
Bristol-Myers SquibbPhase 2
Beyfortus
BeiGenePhase 2
Nolvadex
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FWD1802. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details